Jpmorgan Chase & CO Cor Medix Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Cor Medix Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 194,108 shares of CRMD stock, worth $2.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

194,108

Previous 24,711 685.51%

Holding current value

$2.01 Million

Previous $106,000 1379.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$3.64 - $8.23 $616,605 - $1.39 Million	169,397 Added 685.51%	194,108 $1.57 Million
Q2 2024 Aug 12, 2024	BUY	$4.08 - $6.39 $10,065 - $15,764	2,467 Added 11.09%	24,711 $106,000
Q1 2024 May 10, 2024	SELL	$2.94 - $4.24 $45,514 - $65,639	-15,481 Reduced 41.04%	22,244 $94,000
Q4 2023 Feb 12, 2024	BUY	$3.0 - $4.01 $9,468 - $12,655	3,156 Added 9.13%	37,725 $141,000
Q3 2023 Nov 14, 2023	SELL	$3.6 - $4.46 $86,792 - $107,526	-24,109 Reduced 41.09%	34,569 $127,000
Q2 2023 Aug 11, 2023	BUY	$3.94 - $5.8 $230,423 - $339,201	58,483 Added 29991.28%	58,678 $232,000
Q4 2022 Feb 13, 2023	SELL	$2.81 - $4.45 $60,100 - $95,176	-21,388 Reduced 99.1%	195 $1,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $7.52 $161,557 - $430,820	-57,290 Reduced 72.64%	21,583 $62,000
Q2 2022 Aug 11, 2022	BUY	$2.73 - $5.61 $104,916 - $215,597	38,431 Added 95.03%	78,873 $317,000
Q1 2022 May 11, 2022	BUY	$3.83 - $6.24 $7,537 - $12,280	1,968 Added 5.12%	40,442 $221,000
Q4 2021 Feb 10, 2022	BUY	$4.47 - $5.56 $50,913 - $63,328	11,390 Added 42.05%	38,474 $175,000
Q3 2021 Nov 12, 2021	BUY	$4.46 - $7.11 $120,794 - $192,567	27,084 New	27,084 $126,000

Others Institutions Holding CRMD

# of Institutions

104

Shares Held

17.4M

Call Options Held

134K

Put Options Held

441K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $426M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Cor Medix Inc. Transaction History